We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+31.98%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$3.11B
AUM Growth
+$217M
Cap. Flow
-$278M
Cap. Flow %
-8.93%
Top 10 Hldgs %
51.56%
Holding
91
New
16
Increased
7
Reduced
4
Closed
14

Top Buys

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$76.3M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$56M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$42.7M
4
CYTK icon
Cytokinetics
CYTK
+$38.4M
5
ALGS icon
Aligos Therapeutics
ALGS
+$29.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$383M
2
ALLK
Allakos
ALLK
+$55M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.8M
4
CGEN icon
Compugen
CGEN
+$38.7M
5
QURE icon
uniQure
QURE
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRB icon
76
Cellectar Biosciences
CLRB
$20.5M
$1.91M 0.06%
3,067
– –
ZGNX
77
DELISTED
Zogenix, Inc.
ZGNX
$546K 0.02%
27,300
– –
ACAD icon
78
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-370,000
Closed -$15.3M
ALLK
79
DELISTED
Allakos
ALLK
– –
-675,000
Closed -$55M
ARVN icon
80
Arvinas
ARVN
$518M
– –
-300,000
Closed -$7.08M
CGEN icon
81
Compugen
CGEN
$222M
– –
-2,383,673
Closed -$38.7M
FULC icon
82
Fulcrum Therapeutics
FULC
$273M
– –
-705,882
Closed -$5.6M
KOD icon
83
Kodiak Sciences
KOD
$2.6B
– –
-275,138
Closed -$16.3M
NAUT icon
84
Nautilus Biotechnolgy
NAUT
$124M
– –
-600,000
Closed -$6.27M
RLMD icon
85
Relmada Therapeutics
RLMD
$557M
– –
-300,000
Closed -$11.3M
XENE icon
86
Xenon Pharmaceuticals
XENE
$6.06B
– –
-600,000
Closed -$6.64M
ZYME icon
87
Zymeworks
ZYME
$1.61B
– –
-165,000
Closed -$7.69M
ICPT
88
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-1,176,000
Closed -$48.8M
GBT
89
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-250,000
Closed -$13.8M
LSACU
90
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
– –
-300,000
Closed -$4.08M
IMMU
91
DELISTED
Immunomedics Inc
IMMU
– –
-4,500,000
Closed -$383M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Boxer Capital held 91 positions worth $3.11B, up 7.5% from $2.89B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital withdrew a net $278M in Q4 2020, closing 14 positions and reducing 4 holdings. Its most notable exit was Immunomedics Inc, an estimated $383M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 85% a quarter earlier, followed by Financials.

Against the trend, Boxer Capital opened a new position in ARS Pharmaceuticals worth $77.6M.

  • Boxer Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 1,675,377 shares worth $77.6M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q4 2020, an estimated $76.3M increase.
  • Boxer Capital's biggest Q4 2020 reduction was uniQure, cutting an estimated $21.7M.
  • Boxer Capital fully exited Immunomedics Inc in Q4 2020, selling an estimated $383M.
  • Boxer Capital's ten largest holdings make up 52% of its $3.11B portfolio in Q4 2020.
  • Boxer Capital opened 16 new positions and closed 14 in Q4 2020.
  • Boxer Capital's portfolio value rose 7.5% quarter-over-quarter to $3.11B.

Based on Boxer Capital's 13F filing for Q4 2020, filed 16 Feb 2021.